F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies
ATLANTA, March 31, 2019 — F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, will present four abstracts at the American Association of Cancer Research (AACR) 2019 Annual Meeting in Atlanta from March 29-April 3, 2019 that support novel technologies to treat solid tumor malignancies. F1 Oncology is developing these […]
Taking the Next Step: What We’ve Learned About CAR-T So Far, and What It Means Going Forward
A year ago, flush with the excitement of the FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy for acute lymphoblastic leukemia (ALL), the AACR Annual Meeting focused considerable attention to CAR-T. The approval marked a significant milestone in cancer treatment for researchers and oncologists, which supplied a new ray of hope for […]
Cancer Doesn’t See Borders – And Neither Should Biotech
Headline after headline, we hear about precision medicine and advances in the treatment of challenging diseases that were previously almost always fatal. And thanks to the accelerating scientific advancements in biotechnology, we’re successfully battling subsets of diseases that seemed unbeatable less than a decade ago. Cancer is one example of this trend. No sooner did […]
F1 Oncology’s International Affiliate, Exuma Biotechnology, Announces Acquisition of Strategic Car-T Assets
SHANGHAI and WEST PALM BEACH, Fla., November 13, 2018 — F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, today announced that its international affiliate, EXUMA Biotechnology Hong Kong, has formed Shanghai EXUMA Biotechnology Co., Ltd., a wholly foreign-owned enterprise (WFOE), to acquire all rights to novel chimeric antigen […]
Keynote Announcement: BioFlorida Conference 2018
Morning General Session Speaker Monday, Oct. 15 from 8:55 AM – 9:35 AM Link to full posting
F1 Oncology Announces Development Milestone and $10M Equity Investment
Shanghai, PRC and West Palm Beach, FL – January 7th, 2018 – F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, today announced receipt of a $10 million equity investment from its current investors upon ethics committee approval of a novel precision medicine-directed […]
F1 Oncology’s International Affiliates and Sinobioway Sunterra Biotechnology Announce New Development, Manufacturing, and Supply Agreements to Support cGMP Lentivirus Supply
SHENZHEN, SHANGHAI, HONG KONG AND GRAND CAYMAN–January 7th, 2018–Shanghai Sinobioway Sunterra Biotechnology (SSSB) and F1 Oncology today announced the signing of new development, manufacturing, and supply agreements with plans to complete a new cGMP manufacturing facility in Shenzhen in support of large scale lentivirus contract manufacturing. The new facility, Shenzhen […]
BioAtla and F1 Oncology Announce Global Collaboration to Develop Adoptive Cellular Therapies for Solid Tumors
BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and F1 Oncology, Inc. , a biotechnology company discovering and developing a new class of adoptive cellular therapies (ACTs), today announced a global license agreement to combine BioAtla’s CAB technology with F1 Oncology’s proprietary technolog ies to develop […]
